DDAH1 and prostate cancer: For instance, human DDAH1 inhibitor ZST316 (20) was shown to attenuate vasculogenic mimicry and cell migration in triple negative breast cancer (TNBC) cells.11 Also, DDAH1 inhibitor DD1E5 inhibits the proliferation of human prostate cancer (PCa) cells and NO production while decreasing the amount of vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis and tumor progression in mice.13